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Synaptotagmins interact with APP and
promote Aβ generation
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Abstract
Background: Accumulation of the β-amyloid peptide (Aβ) is a major pathological hallmark of Alzheimer’s disease
(AD). Recent studies have shown that synaptic Aβ toxicity may directly impair synaptic function. However, proteins
regulating Aβ generation at the synapse have not been characterized. Here, we sought to identify synaptic proteins
that interact with the extracellular domain of APP and regulate Aβ generation.
Results: Affinity purification-coupled mass spectrometry identified members of the Synaptotagmin (Syt) family as
novel interacting proteins with the APP ectodomain in mouse brains. Syt-1, −2 and −9 interacted with APP in
cells and in mouse brains in vivo. Using a GST pull-down approach, we have further demonstrated that the Syt
interaction site lies in the 108 amino acids linker region between the E1 and KPI domains of APP. Stable overexpression
of Syt-1 or Syt-9 with APP in CHO and rat pheochromocytoma cells (PC12) significantly increased APP-CTF and sAPP
levels, with a 2 to 3 fold increase in secreted Aβ levels in PC12 cells. Moreover, using a stable knockdown
approach to reduce the expression of endogenous Syt-1 in PC12 cells, we have observed a ~ 50 % reduction
in secreted Aβ generation. APP processing also decreased in these cells, shown by lower CTF levels. Lentiviral-mediated
knock down of endogenous Syt-1 in mouse primary neurons also led to a significant reduction in both Aβ40 and Aβ42
generation. As secreted sAPPβ levels were significantly reduced in PC12 cells lacking Syt-1 expression, our results
suggest that Syt-1 regulates Aβ generation by modulating BACE1-mediated cleavage of APP.
Conclusion: Altogether, our data identify the synaptic vesicle proteins Syt-1 and 9 as novel APP-interacting proteins
that promote Aβ generation and thus may play an important role in the pathogenesis of AD.
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Introduction
Alzheimer’s disease (AD) is one of the most common de-
bilitating neurodegenerative diseases [1]. The neuropatho-
logical hallmarks of AD primarily derive from aggregation
and deposition of misfolded proteins, in particular the β-
amyloid (Aβ) peptide that oligomerizes to form extracellu-
lar senile plaques [2] and the hyperphosphorylated tau
protein that aggregates into neurofibrillary tangles [3, 4].
Numerous studies have shown that AD symptoms directly
correlate with the amount of pathogenic oligomeric Aβ in
the brain [5, 6]. Aβ is generated from the Amyloid Precur-
sor Protein (APP), a type I membrane protein [5, 7]. APP
can undergo either non-amyloidogenic or amyloidogenic
processing depending on the secretases that cleave the
protein. In the non-amyloidogenic cascade, APP is se-
quentially cleaved by α-secretase and γ-secretase thus gen-
erating p3 and AICD fragments [8]. In the amyloidogenic
processing, BACE1 first generates βCTF that is further
processed by the γ-secretase complex to produce patho-
genic Aβ peptides and AICD fragments [9–15]. Aβ pep-
tides oligomerize and aggregate in the form of plaques,
resulting in inflammation and neuronal cell death [16, 17].
APP is a ubiquitously expressed ~105 kDa transmem-
brane glycoprotein [5]. In the brain, APP is found at
both presynaptic and postsynaptic terminals and plays
an important role in various neuronal functions such as
synapse formation, neuronal migration, neurite out-
growth, synaptic plasticity, synaptic transmission and
learning and memory [18–21]. APP is known to traffic
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axonally by interacting with the kinesin light chain and
localize at the presynaptic terminal [22–25]. There, it
undergoes proteolytic processing and releases Aβ at the
synapse [25–27]. Although numerous APP-interacting
proteins have been identified [28, 29], not much is
known about synaptic proteins that interact with the
ectodomain of APP and may regulate Aβ generation.
The Synaptotagmin (Syt) family of proteins is known
to regulate membrane trafficking and fusion [30, 31].
Syts are type-I transmembrane proteins with a short
amino-terminal domain and a large carboxyl-terminal
cytoplasmic region harboring the Ca2+-binding domains
C2A and C2B (Additional file 1: Figure S1B) [30, 32, 33].
Importantly, Syt-1, −2 and −9 are known to act as cal-
cium sensors on synaptic vesicles and play a major role
in synaptic vesicle membrane fusion events [34]. Recent
studies have also shown that APP is present in purified
synaptic vesicle preparations along with its secretases
and Aβ [35, 36].
Here, we performed an unbiased MS-coupled affinity
chromatography screen to search for synaptic proteins that
interact with the extracellular domain of APP. Our study
identifies Syt-1, −2 and −9 as novel APP-ectodomain bind-
ing proteins and demonstrates that Syt-1 is a physiological
interactor of APP. Moreover, we show that both Syt-1
and Syt-9 increase Aβ levels likely via BACE1-mediated
APP processing and thus may play an important role in
Alzheimer’s disease pathology. Overall, our studies reveal
an important novel function for Syt family of synaptic
vesicle proteins in regulating Aβ generation.
Materials and methods
Antibodies and reagents
Rabbit anti-APP antibody and anti-sAPPβ antibodies were
described previously [37]. Syt-1 mouse monoclonal and
Syt-5/9 rabbit polyclonal antibodies were obtained from
Synaptic Systems (Goettingen, Germany). Mouse mono-
clonal anti-GAPDH antibody was purchased from Cell
Signaling (Danvers, MA) while mouse anti-V5 antibody
was from Life Technologies (Grand Island, NY). Anti-Syt-
1 mouse monoclonal antibody (ASV30) and Isopropyl-
beta-D-thiogalactopyranoside (IPTG) were from Thermo
Fisher Scientific (Waltham, MA).
Plasmids construction
To generate NH2-terminal GST-tagged APP ectodomain
constructs, different ectodomain regions of APP were first
amplified with the help of polymerase chain reaction
(PCR) using the following forward and reverse primers, E1
domain: forward, ATATATGTCGACTCTGGAGGTACC
CACTGATGG; reverse, TATATAGCGGCCGCCTAAGC
CAGTGGGCAACACAC; E1+ KPI domain: forward, ATA
TATGTCGACTCTGGAGGTACCCACTGATGG; reverse,
TATATAGCGGCCGCCTAGGCATCAGGGGTACTGGC;
E2 domain: forward, ATATATGTCGACTGCAGCCAGTA
CCCCTGATG; reverse, TATATAGCGGCCGCCTAGGC
CAAGACGTCATCTGAATAG; CBD domain: forward,
ATATATGTCGACTGCAGCCAGTACCCCTGATG; re-
verse, TATATAGCGGCCGCCTATTTGTTTGAACCCA
CATCTTC; APP full-length ectodomain: forward, ATAT
ATGTCGACTCTGGAGGTACCCACTGATGG; reverse,
TATATAGCGGCCGCCTATTTGTTTGAACCCACATC
TTC. For the GST-tagged Syt-1 ectodomain construct,
the entire 57 amino acids long NH2-terminal region of
Syt-1 was amplified using FP: ATATATGGATCCATGGT
GAGCGAGAGTCACCATG, and RP: TATATAGCGGCC
GCCTAGGCCCACGGTGGCAATG. Following amplifica-
tions, APP fragments and the Syt-1 ectodomain were
subcloned in frame with the GST tag into pGEX6P-2
vector (GE Healthcare Life Sciences, Pittsburgh, PA).
Human SCN2B cDNA (BC036793) was obtained from
Harvard Plasmid DNA Resource Core (Harvard Medical
School, Boston, MA). NH2-terminal GST-tagged SCN2B
ectodomain construct was generated by amplifying the
ectodomain coding region of SCN2B using forward
primer, ATATATGGATCCATGGAGGTCACAGTACCTG
CC and reverse primer, TATATAGCGGCCGCCTAGGCC
ACCGTGGAGTCC and then ligated in frame with GST
tag into pGEX6P-2 vector. For generation of COOH-
terminal V5-tag Syt-1, Syt-2 and Syt-9 constructs, the
entire coding region of Syt-1, Syt-2 and Syt-9 were ampli-
fied using the following forward and reverse primers; Syt-1:
forward, ATATATGCTAGCATGGTGAGCGAGAGTCAC
CATG; reverse, TATATAGCGGCCGCCCTTCTTGACGG





AGC. The amplified fragments were then subcloned into
pCDNA6-V5 vector (Life Technologies, Grand Island, NY).
All the generated constructs were sequenced and verified at
the MGH DNA sequencing core facility (Boston, MA).
Generation and purification of GST-tagged recombinant
proteins
GST-tagged ectodomain fragments of APP and SCN2B
were generated and purified using similar methodology
as described earlier [38]. Briefly, plasmids were trans-
formed into E. coli BL21 cells (Life Technologies, Grand
Island, NY) and then allowed to grow at 37 °C until the
optical density of the culture reached between 0.6-1.0.
Cultures were induced by 1 mM IPTG for 3 h at 24 °C.
Cells were lysed and the GST-tagged recombinant pro-
teins were purified by incubating the soluble fractions
with glutathione resin for 4 h at 4 °C. Samples were washed
and stored at 4 °C until further use.
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Glutathione S-transferase (GST) pull-down assay and
Colloidal Blue staining
GST pull-down assays were performed as described pre-
viously [38]. In brief, adult male ICR (CD-1) mice were
purchased from Charles River Laboratory and anaesthe-
tized with the help of Isoflurane (Hospira Inc, IL). Brains
were removed quickly, homogenized in the ice-cold lysis
buffer containing 50 mM HEPES, pH 7.4, 100 mM NaCl,
2 mM EDTA, 1 % Triton X-100 supplemented with pro-
tease and phosphatase inhibitors cocktails (Roche Life
Science, Indianapolis, IN). After removal of the insoluble
fractions, soluble supernatant was incubated at 4 °C with
equal amount of GST-tagged recombinant purified proteins
coupled with glutathione resin. Samples were washed,
eluted out and separated on one-dimensional gel electro-
phoresis using 4-12 % Bis-Tris Gel (Life technologies,
Grand Island, NY). Gels were then subjected to Colloidal
Blue staining and the excised bands were subjected to
mass spectrometry-based analysis.
Protein sequence analysis by LC-MS/MS
Excised Colloidal Blue-stained gel bands were cut into
approximately 1 mm3 pieces and then subjected to a
modified in-gel trypsin digestion procedure as described
previously [39]. Gel pieces were washed, dehydrated with
acetonitrile and then rehydrated with 50 mM NH4HCO3
containing 12.5 ng/μl modified sequencing-grade trypsin
(Promega, Madison, WI) for 45 min at 4 °C. Peptides
were extracted by removing the NH4HCO3 solution,
followed by one wash with a solution containing 50 %
acetonitrile and 1 % formic acid, dried and stored at 4 °C.
On the day of analysis, samples were reconstituted in
HPLC solvent A (2.5 % acetonitrile, 0.1 % formic acid)
and loaded onto a nano-scale reverse-phase HPLC ca-
pillary column via a Famos auto sampler (LC Packings,
San Francisco, CA). Peptides were eluted with the help
of increasing concentrations of solvent B (97.5 % aceto-
nitrile, 0.1 % formic acid), subjected to electrospray
ionization and then entered into an LTQ Velos ion-trap
mass spectrometer (Thermo Fisher, San Jose, CA). Peptides
were detected, isolated, and fragmented to generate a
tandem mass spectrum of specific fragment ions for each
peptide. Peptide sequences (and hence protein identity)
were determined by matching protein databases with the
acquired fragmentation pattern by the software program
Sequest (ThermoFisher, San Jose, CA).
Immunogold electron microscopy
PC12 cells were washed and fixed in a solution contain-
ing 4 % paraformaldehyde and 0.2 % glutaraldehyde in
1X PBS. Following 5 washes, cells were pelleted, resus-
pended in warm 2 % agarose, cut into small blocks and
incubated with 2.3 M sucrose at 4 °C for overnight. Ul-
trathin cryosections were generated on a Leica EM FCS
at −80 °C and collected on the formvar-carbon coated
nickel grids. For double immunolabeling, grids were first
blocked on drops of 1 % BSA and 5 % goat serum and
then incubated with mouse anti-Syt-1 antibody for 1 h
followed by anti-mouse secondary antibody coupled with
10 nm gold particle for 1 h. After rinsing, grids were in-
cubated again with rabbit anti-APP antibody for 1 h
followed by anti-rabbit secondary antibody coupled with
15 nm gold particles. Grids were washed, stained on
drops of Tylose and Uranyl acetate and then allowed to
dry. The grids were examined at 80 kV in a JEOL JEM
1011 transmission electron microscope and the images
were acquired using an AMT digital imaging system
(Advanced Microscopy Techniques, Danvers, MA).
In situ proximity ligation assay (PLA)
In situ proximity ligation assay was performed using the
In situ PLA kit (OLink Bioscience, Sweden) according to
the manufacturer’s protocol. Briefly, PC12 cells were first
blocked and then incubated with rabbit anti-APP (C66)
and mouse anti-Syt-1 antibody for 2 h. Cells were washed
3 times and then incubated with two different in situ
probes for 1 h at 37 °C. After 3 washes, ligation solution
was added to the cells for 30 min followed by polymerase
solution for 2 h. Later, cells were mounted in the mount-
ing medium and visualized under confocal microscope
using 20X objective. Image were captured at identical set-
tings and later processed by Metamorph software.
Generation of Syt-1 and Syt-9 stable cell lines
Syt-1 and Syt-9 stable cell lines were generated on both
CHO-APP [37] and PC12 cells. In brief, CHO-APP and
PC12 cells were transfected with 4 μg of V5-tagged Syt-
1 or Syt-9 cDNA with the help of Effectene transfection
reagent (Qiagen, Valencia). Cells were later trypsinized
and then replated in the presence of 10 μg/μl of Blastici-
din selection marker (Life Technologies, Grand Island,
NY). Cells were grown for 2 weeks before Blasticidin-re-
sistant cells were further plated in a series of serial dilution
in a 96 well tissue culture plate. Single cell colonies were
picked and analyzed by Western blotting for optimal ex-
pression of Syt-1 or Syt-9 with the help of a mouse anti-
V5 antibody.
Primary dissociated neuronal culture
Primary dissociated neuronal culture was prepared as
described previously [37].
Lentiviral infection
Syt-1 shRNA and control DsRed lentiviral particles were
generated at MGH Vector Core facility (Charlestown,
MA). Mouse primary neuronal cultures were infected
with 1 × 106 lentiviral particles at DIV5 and half the
media was replaced 12 h after infection. Cultures were
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allowed to grow for 10 additional days after infection be-
fore analysis of APP processing and Aβ40/42 release.
Immunofluorescence microscopy
Primary neuronal cultures grown on cover glass in 12
well tissue culture plates were fixed at 12 days in vitro
(DIV12) with 4 % paraformaldehyde for 30 min. Cultures
were washed and permeabilized with 0.1 % Triton X-100
and 5 % donkey serum for 1 h at room temperature.
Cells on coverglass were then incubated with rabbit
anti-APP (C66) and mouse anti-Syt-1 antibodies at 4 °C
for overnight. Following washing, cells were again incu-
bated with Alexa Fluor488-conjugated anti-rabbit and
Alexa568-conjugated anti-mouse secondary antibodies
for 2 h at room temperature. Cells on coverglass were
then washed and then mounted on glass slides with the
help of DAPI containing mounting media (Life Tech-
nologies, Grand Island, NY). Images were acquired on
Olympus IX-70 microscope at similar exposure settings
and later processed by IP lab software.
Western blot analysis
Cells were lysed in 1X GTIP buffer (10 mM Tris–HCl,
pH 6.8, 150 mM NaCl, 2 mM EDTA, 1 % Triton X-100
and 0.25 % Nonidet P-40) supplemented with protease
and phosphatase inhibitors cocktail. The soluble fraction
was obtained by centrifugation and the protein concentra-
tion was measured with the help of a BCA protein assay
kit (Pierce Biotechnology, Rockford, USA). 40–60 μg of
protein samples were separated by gel electrophoresis
using 4-12 % Bis-Tris gels and later transferred on PVDF
membranes (Bio-Rad, Hercules, CA). Membranes were
blocked with 5 % skimmed milk for 1 h at room
temperature and then incubated with the indicated primary
antibodies overnight at 4 °C at the following dilutions:
rabbit anti-APP (C66) 1:1000, mouse anti-V5 1:5000,
mouse anti-Syt-1 1:1000, rabbit anti Syt-9 1:1000, rabbit
anti-sAPPβ 1:250, mouse anti-sAPPα 1:1000. Following in-
cubation with HRP-conjugated secondary antibodies, blots
were developed with the help of ECL chemiluminiscence
detection reagent using Biomax film (Kodak).
Aβ ELISA
CHO cells and PC12 cells stably expressing Syt-1 or Syt-9
and PC12 Syt-1 stable KD cells were plated on 60-mm
tissue culture plates. Conditioned media was collected
after 24 h and subjected to standard sandwich ELISA
for measurement of secreted Aβ40 and Aβ42 using an
Aβ ELISA Human/Rat kit (Wako Pure chemical). Aβ40
and Aβ42 from mouse primary neuronal cultures were
determined by performing sandwich ELISA on condi-
tioned media using 21F12/2G3 as capture antibody for
Aβ42/ Aβ40 and 266 (Abeta13-26) as detector. Aβ
values were normalized by the cellular protein amount
and expressed as pg/ml/mg.
Statistical analyses
All statistical analyses were performed using a 2-tailed
Student’s t test. Error bars represented in graphs denote
the SE.
Results
Unbiased proteomic analysis of APP ectodomain-interacting
proteins
Proteins that regulate Aβ generation at the synapse are
largely unknown. In an effort to identify these proteins,
we employed an unbiased mass spectrometry-based
proteomic screen using GST-tagged APP ectodomain
regions as baits. The five APP ectodomain protein frag-
ments used in these experiments are listed in Additional file
1. Figure S1A: full ectodomain of APP (GST-APP), E1
domain (GST-E1), E1 and KPI domains together (GST-
E1 +KPI), E2 domain (GST-E2), and E2 and carbohydrate-
binding domains together (GST-CBD). Immobilized
GST-tagged recombinant proteins were used to pull-down
interacting proteins from adult mouse forebrains extracted
in 1 % Triton X-100 lysis buffer. The interacting protein
complexes were separated by one-dimensional gel electro-
phoresis, stained with Colloidal Blue stain and the excised
bands were subjected to mass spectrometry analysis
(Harvard Taplin MS facility). As shown in Fig. 1a, each
GST-tagged APP ectodomain fragment pulled down
distinctive sets of protein bands indicative of multiple
interacting proteins. Moreover, these Colloidal Blue-stained
bands were not visible in the GST tag alone fraction
suggesting specific association of these proteins with
the APP domains and not with the GST tag.
Mass spectrometry analysis of the Colloidal Blue-stained
bands revealed numerous proteins in each fraction. As
shown in Fig. 1b, our unbiased screen successfully
identified a large number of peptides belonging to pro-
teins already known to interact with the APP ectodomain
[40–43], validating the specificity of our proteomic screen.
In addition to the known APP ectodomain-interacting
proteins, we have found multiple novel proteins as well.
Based on the number of peptides and spectra, our screen
identified Synaptotagmin-1, −2, and −9 as major APP
ectodomain binding proteins (Fig. 1c). Syts account for
a total of 89 peptides in ~50-70 kDa bands (Fig. 1c).
The number of Syt peptides identified is in the order of
peptides that were detected for multiple known APP
ectodomain-interacting proteins in our unbiased assay,
suggesting that the Syt family of proteins is a potentially
strong APP-interacting protein family. All three Syts were
found in both the GST-APP (full-length ectodomain) and
the GST-E1 + KPI fractions. Other fractions of APP, GST
alone, or the GST-SCN2B ectodomain did not contain any
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Syt peptides, confirming the specificity of our assay. Since
the E1 domain alone did not pull down Syts, our data sug-
gest that this protein family preferentially interacts with
the KPI domain or the region surrounding the KPI do-
main. Altogether, these data suggest that Syts are novel
APP-interacting proteins.
APP interacts with Syt-1, Syt-2 and Syt-9
To directly assess whether Syt-1, Syt-2 and Syt-9 interact
with APP, we performed co-immunoprecipitation experi-
ments. CHO cells stably co-expressing APP and Syt-1,
Syt-2, or Syt-9 were lysed and immunoprecipiated with
anti-APP C66 antibodies. As shown in Fig. 2, APP
antibodies successfully pulled down bands around ~
50–70 kDa specific for Syt-1, Syt-2, and Syt-9 (Figs. 2a, b,
and c respectively). In a reverse co-immunoprecipitation
assay, anti-V5 antibodies against V5-tagged Syts were also
able to pull down both mature and immature forms of
APP from stably expressing CHO cells (Figs. 2a, b, and c).
The association of APP with different forms of Syt family
members was specific, as neither APP nor Syt-1, −2 or −9
were significantly detected in the control IP fraction with
IgG (Figs. 2a, b, and c). This data suggest that APP inter-
acts with all three isoforms of Syts in cells.
Next, we performed co-immunoprecipitation assays
from adult mouse forebrains to test whether Syt-APP
complexes also exist in vivo. Adult mouse forebrains
were extracted with 1 % Triton X-100 and incubated
with either anti-APP C66 antibodies or mouse anti-
Syt antibodies along with the appropriate control IgG
antibodies. As shown in Fig. 2d, both mature and im-
mature forms of APP were pulled down with Syt-1
and Syt-9 specific antibodies but not with control IgG
antibodies from adult mouse forebrains. Conversely,
anti-APP antibodies also co-immunoprecipitated Syt-1
from forebrains (Fig. 2d). As Syt-2 specific antibodies
are not commercially available, we were not able to test
whether APP also exists in complex with Syt-2 in vivo.
Taken together, these data clearly demonstrate that all
three Syts form complexes with APP in vitro and Syt-1
and −9 in vivo, and further validate our initial unbiased
proteomic screen results that Syt-1, −2 and −9 are novel
APP-interacting proteins.
Syt-1 is a physiological interactor of APP
In addition to co-immunoprecipiation assays, we also
performed image-based analysis experiments to detect
physiological interaction between endogenous APP and
Syt-1. PC12 cells derived from rat adrenal glands have
previously been used as a well-defined model to study
Syt-1 protein function. In PC12 cells, Syt-1 is known to
reside in large dense core vesicles (LDCVs) that resemble
Fig. 1 Mass spectrometry-based identification of novel APP-interacting proteins. a Colloidal Blue-stained gel of APP-interacting proteins from
mouse forebrain extracts. The proteins were pulled down with GST-tagged APP-ectodomain regions. Red asterisks denote purified GST-tagged
APP-ectodomain fragments while arrows point to the bands that were excised and subjected to MS-based analysis for protein identification.
Arrowheads denote bands containing Syt peptides. b MS-based confirmation of previously identified APP ectodomain-interacting proteins. c
MS-based identification of Syt-1, Syt-2 and Syt-9 peptides. Peptides from all three Syts were pulled down by GST-APP and GST-E1 + KPI. Other
GST-tagged APP fragments did not pull down Syt peptides (not shown)
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synaptic vesicle morphology in neuronal cells [44, 45]. We
next performed electron microscopy (EM) analysis to de-
tect interaction between endogenous APP and Syt-1 pro-
teins residing in PC12 cell vesicles. PC12 cells were fixed
and ultrathin cryosections were subjected to double-
immunogold labeling using specific primary antibodies
against APP and Syt-1. As shown in Fig. 3a, immunogold
labeling revealed a potential oligomerization pattern of
Syt-1 by itself. Interestingly, the majority of the large gold
particle-labeled APP protein was observed in close prox-
imity with the cluster of Syt-1 proteins (Fig. 3a, insert).
Quantitative analysis revealed that ~70 % of APP was
found clustered with Syt-1 with a distance between the
two gold particles of less than 30 nm (Fig. 3b). This indi-
cates robust co-localization between the two proteins.
We further validated the interaction between APP and
Syt-1 at an endogenous level by an in situ proximity
ligation assay (PLA) and immunofluorescence analysis.
In situ PLA was performed in PC12 cells. PC12 cells
were fixed and then subjected to Duolink in situ PLA
using anti-APP (C66) and anti-Syt-1 antibodies. Co-
localization of Syt-1 and APP antibodies together in
intact PC12 cells resulted in a significant increase in
polymerization and ligation of in situ probes. These
Fig. 2 APP interacts with Syt-1, −2 and −9 in vitro and in vivo. a Western blot analysis of APP and Syt-1 co-immunoprecipitates. CHO cells stably
coexpressing APP and V5-tagged Syt-1 were subjected to immunoprecipitation using specific APP (C66) or V5-tag antibodies. Syt-1 or APP
specific bands were identified in the immunoprecipitates but were not observed in the control IgG pull-down (n = 3 for each condition). b
Co-immunoprecipitation of APP and Syt-2. APP or Syt-2 were immunoprecipitated from CHO cells expressing Syt-2 (V5-tag) and probed with
anti-V5 or APP (C66) antibodies. APP specific bands were identified in the fraction immunoprecipitated with anti V5 antibody (Syt-2) while Syt-2
specific bands were identified in the APP pull-down (n = 3 for each condition). c Western blot analysis showing co-immunoprecipitation of APP
with Syt-9. CHO cells stably co-expressing APP and V5-tagged Syt-9 were subjected to immunoprecipitation using specific APP (C66) or V5-tag
antibodies. Syt-9 or APP specific bands were identified in the immunoprecipitates but were not observed in the control IgG pull-down (n = 3 for
each condition). d Western blot analysis of APP and Syt-1 or Syt-9 co-immunoprecipitates from adult mouse forebrain. Specific antibodies against
endogenous Syt-1 or Syt-9 were used to immunoprecipitate Syt-1 or Syt-9 and probed with an anti-APP antibody. Western blot shows
APP-specific staining in both Syt-1 and Syt-9 immunoprecipitates as compared to the IgG controls. In a reverse co-immunoprecipitation
assay, the APP-specific antibody co-immunoprecipiated Syt-1 (n = 2 for each condition)
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were visualized as fluorescent red dots, indicating dir-
ect interaction between Syt-1 and APP in PC12 cells
(Fig. 3c left panel). On the other hand, no fluorescent
red dots were observed in the negative control when
PC12 cells were labeled with only one primary antibody
either against APP or Syt-1 (Fig. 3c right panel). Immuno-
fluorescence analyses were carried out in primary neur-
onal cultures. Dissociated primary neuronal cultures at
DIV12 were fixed, permeabilized and subjected to APP
and Syt-1 labeling together using specific antibodies. As
shown in Fig. 3d, robust colocalization of APP (green)
with Syt-1 (red) was observed in the neuronal cell body as
well as in the neurites. Altogether, these data show that
APP interacts with Syt-1 at an endogenous level both in
PC12 cells and in primary neurons.
Syts interact with the linker sequence between the E1
and KPI domains of APP
Our unbiased APP ectodomain-interacting protein screen
identified multiple peptides that belong to three different
members of Syt family of proteins. Other than the GST-
APP full ectodomain fraction, multiple Syt peptides were
also found in the GST-E1 + KPI domain fraction but not
in any other GST fractions. These initial results suggested
that the KPI domain of APP or the 108-amino acids
Fig. 3 Syt-1 is a physiological interactor of APP. a Electron microscopic (EM) images of ultra-thin cryosections of naïve PC12 cells show double
immunogold labeling of endogenous APP (15 nm) with Syt-1 (10 nm). White arrows depict co-localization of APP with Syt-1 while the inserts
show 300 % magnification of APP in close association with Syt-1. Analysis was based on three independent sets of experiments. b Quantitative
analysis of immunogold labeling of APP in cluster with Syt-1 compared to APP alone, as revealed by a. c In situ PLA shows interaction between
endogenous APP and Syt-1 in naïve PC12 cells. Fluorescence red dots represent close association between APP and Syt-1 (left panel) as compared
to the negative control (right panel). Images were taken at identical settings. Nuclear staining with DAPI is shown in blue. Analysis was based on
three independent sets of experiments. d Immunofluorescence microscopy images of mouse primary neuronal cultures stained with APP and
Syt-1 specific antibodies. Co-localization between APP (green) and Syt-1 (red) was observed in the cell body and in neurites. Images were
obtained at identical settings. Analysis was based on three independent sets of experiments
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region between the E1 and KPI domains represent the pri-
mary site of Syt interaction with the APP ectodomain.
To confirm this initial result, we employed a direct in
vitro GST pull-down assay. CHO cells were transiently
transfected with V5-tagged Syt-1, −2, or −9 isoforms and
exposed to the immobilized GST-APP ectodomain frag-
ments. Western blot analysis revealed that GST-APP
pulled down two or more bands for all three Syts (Fig. 4).
The presence of two or more Syt bands is likely due to
known glycosylation-dependent post-translational modifi-
cations of these proteins [32]. All forms of all three Syts
were specifically pulled down with the GST-tagged APP
ectodomain and GST-E1 + KPI fragments but not the
other APP ectodomain fragments (Fig. 4a). We have not
excluded that APP may prefer one form of Syt over an-
other. A very weak nonspecific interaction of Syt-2 was
also observed with the E2 domain of APP. These data in-
dicate that the KPI domain and/or the region between the
E1 and KPI domains serve as the primary site of Syt inter-
action on APP.
Next, we asked whether the KPI domain or the region
between the E1 and KPI domains mediate the inter-
action of APP with Syts. For this purpose, we first engi-
neered a stop codon at the beginning of the KPI domain
and then generated the purified APP ectodomain frag-
ment (GST-APP289) that contains the E1 domain and
the 108 amino acids linker between the E1 and KPI
domain but not the KPI domain. CHO cells stably
Fig. 4 APP interacts with Syt-1 and Syt-9 via its linker region between the E1 and KPI domain. a In vitro GST pull-down assay of Syt-1, −2 and −9.
GST-tagged APP-ectodomain fragments were used to pull down V5-tagged Syt-1, −2 and −9 from stably expressing CHO cells. Western blot
analysis with anti-V5 antibodies revealed specific interaction of Syt-1, −2 and −9 with both GST-APP-ectodomain and GST-E1 + KPI fragments.
Analysis was based on 4 different sets of experiments. b In vitro GST pull-down assay showing interaction of Syt-1 and Syt-9 with the linker region
of APP between the E1 and KPI domain. The GST-tagged APP-289 fragment (containing the linker region but not the KPI domain) pulled down
both Syt-1 and Syt-9 while the GST-E1 domain did not. Analysis was based on three different sets of experiments. c Co-immunoprecipitation of
the APP695 isoform with Syt-1 and Syt-9. CHO cells stably expressing APP695 were transfected with V5-tagged Syt-1 or Syt-9. Western blot analysis
shows specific co-immunoprecipitation of APP695 with V5-tagged Syt-1 and Syt-9 (n = 3 for each condition). d In vitro GST pull-down assay
showing that the Syt-1 N-terminal region interacts with APP. Purified GST-Syt1 N-terminal region pulled down full-length APP while no interaction
was observed with control GST. Bottom panel shows separate colloidal blue stained gel of purified GST and GST-Syt1 N-terminal purified proteins
used for the APP pull-down assay. Analysis was based on four different sets of experiments
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expressing either V5-tagged Syt-1 or Syt-9 were lysed
and the cell lysate was then exposed to various immo-
bilized GST-tagged APP ectodomain fragments. The
GST-APP289 region, but not the GST-E1 or GST alone
fragments, was able to pull down Syt-1 and Syt-9 from
CHO cells (Fig. 4b).
To directly demonstrate that the KPI domain is not
essential in mediating APP-Syt-1/Syt-9 interaction, we
performed co-immunoprecipitation experiments using
the APP695 isoform that lacks the KPI domain. CHO
cells stably transfected with APP695 were transiently
transfected with either V5-tagged Syt-1 or Syt-9 and
the cell extracts were immunoprecipitated using anti-
V5 antibodies. Syt-1 and Syt-9 were able to pull-down
both mature and immature form of the APP695 iso-
form as compared to the control IgG, confirming that
the KPI domain is dispensable for APP and Syt-1/Syt-9
interaction (Fig. 4c). These data show that the linker re-
gion between the E1 and KPI domain, and not the KPI
domain, mediates the interaction of APP with Syts.
As Syt-1 interacts with APP ectodomain region, we next
tested whether the APP interaction site lies in the lumenal
N-terminal region of Syt-1. Similarly to the APP ecto-
domain constructs, the entire Syt-1 N-terminal lumenal
region of 57 amino acids was GST-tagged, expressed,
purified and used as a bait to pull-down APP in an in
vitro GST pull-down assay (Additional file 1: Figure
S1B). As shown in the Fig. 4d, APP was pulled down
with the Syt-1 N-terminal fragment while no binding
was observed with the control GST tag alone. This sug-
gests that Syt-1 and APP most likely interact through
their lumenal N-terminal ectodomain regions.
Syt-1 and Syt-9 regulate APP processing and Aβ
generation
As both Syt-1 and Syt-9 interact with APP in cells and in
mouse brains, we next tested the effect of Syt-1 and Syt-9
expression on APP metabolism and Aβ generation. Syt-1
or Syt-9 were stably co-expressed with APP in CHO cells
and the cell lysate was subjected to Western blot analysis
using an anti-APP antibody (C66). Stable overexpression
of either Syt-1 or Syt-9 in CHO cells significantly in-
creased APP-CTFs levels as compared to only APP-
expressing cells while no changes were observed in
mature or immature APP levels (Fig. 5a).
As overexpression of Syts regulate APP processing in
CHO cells, we next analyzed the effect of Syt-1 or Syt-9
expression on Aβ levels in the same system. Conditioned
media from CHO cells stably co-expressing Syt-1 or Syt-9
with APP was subjected to Aβ40 and Aβ42 ELISAs as de-
scribed in the methods section. Stable co-expression of
Syt-1 with APP caused a ~30-fold increase in Aβ40 levels
and a ~39-fold increase in Aβ42 while a ~25-fold increase
in Aβ40 and Aβ42 levels was observed in cells expressing
Syt-9 with APP (Fig. 5b).
Stable over expression of Syt-1 or Syt-9 enhanced APP
processing as seen by elevated APP-C83 and APP-C99
levels, suggesting that Syt-1 and Syt-9 affect both α- and
β-cleavage of APP. To test this, we also analyzed sAPPα
and sAPPβ levels in the conditioned media of CHO cells
expressing Syt-1 or Syt-9 with APP. Fig. 5a and c show
significantly elevated levels of both sAPPα and sAPPβ in
cells expressing either Syt-1 or Syt-9 as compared to
APP-expressing cells. Together, our results indicate that
expression of Syt-1 and Syt-9 in CHO cells markedly ele-
vates APP-CTFs, sAPP and Aβ levels.
Syt-1 and Syt-9 regulate endogenous APP-CTF and Aβ
levels in PC12 cells
While expression of Syt-1 or Syt-9 dramatically increases
APP-CTF and Aβ levels in CHO cells expressing APP,
CHO cells do not exhibit neuronal characteristics. Thus,
we next tested the effect of Syt-1 and Syt-9 expression
on endogenous APP processing in PC12 cells. PC12 cells
stably expressing either Syt-1 or Syt-9 were lysed and
the lysates were subjected to Western blot analysis using
the anti-APP (C66) antibody. No significant changes in
full-length APP levels were observed with either Syt-1 or
Syt-9 expression in PC12 cells. However, both Syt-1 and
Syt-9 significantly elevated endogenous APP-CTF levels
in PC12 cells as compared to the parental cells (Fig. 6a).
Endogenous APP-C99 could not be clearly distinguished
from APP-C83 in PC12 cells.
In addition to APP-CTFs, we also analyzed the effect
of Syt-1 or Syt-9 expression on endogenous Aβ levels.
Conditioned media collected from the PC12 cells ex-
pressing Syt-1 and Syt-9 were subjected to Aβ40 and
Aβ42 ELISAs. A ~ 2- to 3-fold increase in Aβ40 and Aβ42
levels were observed with the expression of Syt-1 or Syt-
9 in PC12 cells as compared to parental cells (Fig. 6b).
Taken together, data obtained from both CHO-APP cells
and native PC12 cells show that expression of Syt-1 and
Syt-9 increases endogenous APP-CTF and Aβ40 and
Aβ42 levels.
Syt-1 knockdown reduces APP-CTF, sAPPβ and Aβ levels
In order to assess the role of endogenous Syt-1 expression
in the regulation of APP metabolism, we next used a
knockdown approach to lower the expression of endogen-
ous Syt-1 and analyze its effect on APP metabolism and
Aβ levels. PC12 cells that stably express shRNA against
Syt-1 were generated and characterized as described earl-
ier [46, 47]. Wild type (WT) and Syt-1 knockdown (KD)
PC12 cells were plated and the cell lysates were subjected
to Western blotting with an anti-APP (C66) antibody. A
significant reduction in APP-CTF levels was observed in
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Fig. 5 Syt-1 and Syt-9 modulate APP processing and Aβ levels in CHO cells. a Western blot analysis of CHO cells stably co-expressing Syt-1 or
Syt-9 with APP shows a significant increase in APP-CTFs, sAPPα and sAPPβ levels as compared to the control CHO-APP cells. Syt-1 and Syt-9
expression was confirmed using anti-V5 tag antibodies and a GAPDH antibody was used for equal protein loading. b Sandwich ELISA from the
conditioned media indicates a strong increase in Aβ40 and Aβ42 release from cells expressing Syt-1 or Syt-9 as compared to the control CHO-APP
cells. c Quantitative analysis of total sAPPβ levels in the conditioned media of CHO cells co-expressing Syt-1 or Syt-9 with APP as compared to
only APP expression (student t test; **, p < 0.01; n = 4 for each condition)
Fig. 6 Expression of Syt-1 and Syt-9 in PC12 cells increases endogenous APP-CTF and Aβ levels. a Western blot analysis shows that stable
expression of Syt-1 or Syt-9 in PC12 cells increases endogenous APP-CTF levels. Bottom panel shows expression of Syt-1 and Syt-9 and a GAPDH
antibody was used for equal protein loading. b Quantitative analysis of sandwich ELISA from the conditioned media of PC12 cells co-expressing
Syt-1 or Syt-9 with APP. Expression of Syt-1 or Syt-9 in PC12 cells causes a robust increase in secreted Aβ40 and Aβ42 levels as compared to the
control APP-expressing cells (student t test; *, p < 0.05; **, p < 0.01; n = 4 for each condition)
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Syt-1 KD PC12 as compared to wild type cells, while no
changes were noted in full-length APP levels (Fig. 7a).
In addition to stable expression of shRNA against Syt-1,
we also employed a siRNA-based strategy to transiently
knock down the endogenous expression of Syt-1 and con-
firm a decrease in APP-CTF levels. A 90-95 % reduction
in endogenous Syt-1 expression was observed, as revealed
by Syt-1 specific antibody. Transient expression of Syt-1
specific siRNAs resulted in significant reduction of en-
dogenous APP-CTF levels in PC12 cells, without changing
full-length APP levels (Additional file 1: Figure S2).
We also measured secreted Aβ40 and Aβ42 levels in
PC12 cells with reduced Syt-1 expression. Conditioned
media from both WT and stable Syt-1 KD PC12 cells
were collected and subjected to Aβ40 and Aβ42 ELISAs.
Decreased Syt-1 expression resulted in a 48 % reduction in
secreted Aβ40 levels with a concomitant 53 % decrease in
Aβ42 levels, as compared to the WT PC12 cells (Fig. 7b).
Lack of Syt-1 expression in PC12 cells lowers endogen-
ous APP-CTF generation and secreted Aβ40 and Aβ42
levels, suggesting that Syt-1 may regulate BACE1-mediated
cleavage of APP. To test this, we analyzed secreted sAPPβ
in WT versus Syt-1 KD PC12 cells. Figures 7c and d show
that stable Syt-1 KD PC12 cells release ~ 30 % less sAPPβ
in the conditioned media as compared to the WT PC12
cells. All together, these results indicate that endogenous
Syt-1 promotes BACE1-mediated cleavage of endogenous
APP in PC12 cells.
Syt-1 regulates Aβ levels in mouse neurons
Using both over expression and knock down strat-
egies, we have clearly shown that Syt-1 is an important
Fig. 7 Stable knockdown of Syt-1 reduces endogenous APP-CTF, Aβ and sAPPβ levels in PC12 cells. a Stable knockdown of Syt-1 in PC12 cells
reduces endogenous APP-CTF levels as revealed by Western blot analysis. Knock down of Syt-1 was confirmed with a Syt-1 specific antibody
(Synaptic Systems) and a GAPDH antibody was used for equal protein loading. b Quantitative analysis of sandwich ELISA shows lower Aβ40 and
Aβ42 levels in the conditioned media of the PC12 cells with stable Syt-1 KD as compared to the WT cells (student t test; **, p < 0.01; n = 3 for each
condition). c Western blot analysis of conditioned media shows a significant reduction in total sAPPβ levels in stable Syt-1 KD PC12 cells as
compared to the WT cells. d Quantitative analysis of total sAPPβ levels in the conditioned media of the WT PC12 cells and stable Syt-1 KD PC12
cells (student t test; **, p < 0.01; n = 3 for each condition)
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regulator of APP processing and Aβ generation in
PC12 cells. To study if Syt-1 modulates APP processing
and Aβ generation in mouse primary neurons, we
employed a lentiviral-mediated approach to knock down
endogenous Syt-1 expression. A lentiviral vector that ex-
presses shRNA against mouse Syt-1 was used to knock
down Syt-1 expression along with an empty control vec-
tor. Mouse primary neuronal cultures were infected with
lentiviral vectors at DIV5 and the cultures were main-
tained for 10 additional days before analysis for APP CTFs
levels and Aβ40/Aβ42 generation. As shown in the Fig. 8a,
lentiviral-mediated infection of mouse primary neuronal
cultures led to ~70 % reduction in Syt-1 expression levels
as compared to the control. Interestingly, when we ana-
lyzed the conditioned media from the infected cultures,
we observed a significant 18-19 % reduction in secreted
Aβ40 and Aβ42 levels with Syt-1 knock down as compared
to the controls (Fig. 8b). The continued expression of low
levels of Syt-1 and other Syts in these cultures may have
compensated for the loss of function of Syt-1 in the
neuronal system as compared to the PC12 cells. Indeed,
we had observed interaction between APP and other
members of the Syt family. Thus, a ~20 % reduction in
Aβ40 and Aβ42 levels in the mouse primary culture sys-
tem is expected. All together, our data show that Syt-1
is an endogenous regulator of Aβ generation in mouse
primary neurons.
Discussion
APP regulates numerous physiological functions in brain,
but it is also cleaved to generate Aβ species involved in
the pathology of the Alzheimer’s disease [48–50]. To
understand how APP functions are regulated in both
physiological and pathological conditions, numerous stud-
ies have focused on the identification of APP-interacting
proteins [28, 29, 51]. Although these studies identified
some mouse brain APP-associated proteins, these mainly
bound to the APP-CTF. Only a few proteins such as
contactin, F-spondin and Nogo-66 have been reported
so far to interact with the APP extracellular domains
[41, 52, 53].
Here, we performed an unbiased proteomic screen using
purified GST-tagged APP-ectodomain fragments and have
identified members of the Synaptotagmin family as novel
APP-ectodomain interacting proteins. Using transgenic
mice, previous studies had identified Syt-1 and Syt-11 as
pulling down with APP and thus suggested a close associ-
ation between these Syts and APP [29, 54]. However, these
studies have not characterized the interaction between
APP and Syts and its effect on APP processing. Our data
Fig. 8 Lentiviral-mediated knock down of Syt-1 reduces endogenous Aβ levels in mouse primary neuronal culture. a Western blot analysis of APP
CTF levels in mouse primary neurons infected with lentiviral shRNA against Syt-1. Reduction in the endogenous expression of Syt-1 was confirmed
using a Syt-1 specific antibody (Synaptic Systems) while GAPDH staining was used to ensure equal protein loading. b Quantitative analysis of
Aβ40 and Aβ42 levels from the conditioned media of mouse primary neurons infected with a control vector and lentiviral vector expressing Syt-1
shRNA. Lentiviral-mediated knock down of endogenous Syt-1 in mouse primary neuronal cultures significantly decreases secreted Aβ40 and Aβ42
levels as compared to the control vector (student t test; *, p < 0.05; n = 3 for each condition)
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not only identify Syt-1 as an APP-interacting protein but
also show that Syt-1, −2, and −9 exist in complex with
APP both in vitro and in vivo, the interaction is mediated
by APP’s linker region between the E1 and KPI domains,
and it results in altered APP processing.
The 17 different isoforms of Synaptotagmins not only
differ in structure but also in subcellular localization [55,
56]. Syt-1 and Syt-2 were shown to localize to synaptic
vesicles while Syt-9 is targeted to both axons and den-
drites [57]. Recently, it was shown that APP is localized
to synaptic vesicles and trafficked via neuronal activity-
dependent release of synaptic vesicles [36]. The interaction
of Syts with APP could mediate the localization of APP to
synaptic vesicles and its activity-dependent localization to
presynaptic membranes. Syt-1 is the best-characterized
isoform among the Synaptotagmin family of proteins.
Syt-1 acts as a dual sensor as it regulates both the fu-
sion of synaptic vesicles to the pre-synaptic membrane
as well as their endocytosis [58]. Endocytosis has been
shown to play an important role in the generation of Aβ
as APP is endocytosed via a clathrin-mediated process
from the plasma membrane into endosome-like structures
to generate Aβ peptides [59, 60]. These studies suggest the
possibility that Syt-1 containing vesicles may acquire APP
during synaptic vesicle endocytosis from the presynaptic
membrane and regulate APP processing and Aβ gener-
ation in the endosomes. However, the precise role of Syt-1
in APP trafficking, localization, and metabolism warrants
further investigation.
APP is known to localize both at the presynaptic and
postsynaptic terminals where it acts as a trans synaptic
adhesion molecule and promotes synapse formation
[18]. Presence of APP at the synapse regulates synaptic
transmission and neurotransmitter release, best shown
in APP/APLP2 double knockout mouse models. Indeed,
APP/APLP2 double knockout mice exhibit reduced syn-
aptic vesicle density, active zone size, and number of
docked synaptic vesicles per active zone as compared to
APLP2 single knockout [21, 61, 62]. Moreover, overex-
pression of APP in PC12 cells promoted exocytosis and
increased basal and constitutive secretion [63]. Given
the essential role of Syt-1 in synaptic vesicle exocytosis,
docking and neurotransmitter release [30], its interaction
with APP may regulate its function. This could partially
or fully explain altered synaptic vesicle biology in APP
knockout mice. Future studies will be needed to fully
explore the role of APP in regulating Syt-1-mediated
synaptic vesicle exocytosis and endocytosis.
Evidence suggests that APP undergoes BACE1 and
PS1/γ-secretase-dependent proteolytic processing in
the presynaptic compartments where it may generate
Aβ peptides released from the nerve terminals [25].
Genetic inactivation of PS1 in the presynaptic compartment
significantly increases APP-CTF accumulation, supporting
a role for the presynaptic compartment as a major site for
APP processing and Aβ generation [64]. In addition, PS1
and other γ-secretase complex components were found in
purified synaptic vesicle preparations from adult rat brain
[35]. Similarly to the γ-secretase complex components,
BACE1 was also found in the synaptic vesicle fraction
[36, 65]. Moreover, using a transgenic AD mouse model,
Vassar et al. have observed strong colocalization of BACE1
with APP in the swollen dystrophic presynaptic terminals
surrounding Aβ plaques [66]. This suggests abnormal accu-
mulation of BACE1 at presynaptic sites and enhanced
BACE1-mediated processing of APP, potentially con-
tributing to AD pathogenesis. Our results indicate that
an APP-interacting protein, Syt-1, regulates APP pro-
cessing in the presynaptic compartment. Specifically,
our data suggest that Syt-1 modulates BACE1-mediated
cleavage of APP as overexpression of Syt-1 enhanced
sAPPβ and Aβ levels while loss of Syt-1 in PC12 cells
resulted in lower endogenous Aβ generation and sAPPβ
levels in the conditioned media with decreased APP-CTF
levels. Moreover, our results indicate that Syt-1 also regu-
lates α-cleavage of APP and loss of Syt-1 may also impair
α-cleavage as we have observed increased sAPPα in Syt-1
overexpressing cells. BACE1-mediated cleavage of APP in
presynaptic vesicles was previously reported [65]. Interest-
ingly, the pH of synaptic vesicles is around 5.0 - 5.7, which
would allow for an ideal microenvironment for optimal
BACE1 activity and Aβ generation [67, 68]. Given the
essential role of Syt-1 in synaptic vesicle biology and
trafficking, it is very likely that BACE1-mediated cleavage
of APP and Aβ generation are regulated by Syt-1 particu-
larly in synaptic vesicles. Thus, Syt-1 interaction with APP
could represent a novel therapeutic target in the treatment
or prevention of AD.
Additional file
Additional file 1: Figure S1. Schematic representation of GST-tagged
APP and Syt-1 ectodomain. (S1A) Schematic diagram of APP structure
(top) and GST-tagged APP ectodomain (bottom) constructs used in
MS-based identification of APP-interacting proteome from mouse brain.
(S1B) Schematic representation of Syt-1 structure (top) and GST-tagged
Syt-1 N-terminal (lumenal region) construct. Figure S2. Syt-1 siRNA
decreases endogenous APP-CTF levels in PC12 cells. Western blot analysis
of PC12 cells transiently transfected with Syt-1 specific siRNA shows lower
APP-CTF levels as compared to the control cells. Top panel shows
full-length APP and APP-CTF levels while bottom panel shows Syt-1
expression. GAPDH staining was used for equal protein loading.
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